Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus
Karin Rådholm, Gemma A. Figtree, Vlado Perkovic, et al.
Circulation (2018) Vol. 138, Iss. 5, pp. 458-468
Open Access | Times Cited: 437

Showing 1-25 of 437 citing articles:

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 24, pp. 2295-2306
Open Access | Times Cited: 4866
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetes Care (2018) Vol. 41, Iss. 12, pp. 2669-2701
Open Access | Times Cited: 3166
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker, Stephen D. Wiviott, Itamar Raz, et al.
The Lancet (2018) Vol. 393, Iss. 10166, pp. 31-39
Closed Access | Times Cited: 2392
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetologia (2018) Vol. 61, Iss. 12, pp. 2461-2498
Open Access | Times Cited: 1349
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma, John J.V. McMurray
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2108-2117
Open Access | Times Cited: 793
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Piotr Ponikowski, Stefan D. Anker, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1169-1186
Open Access | Times Cited: 580
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri Kato, Michael G. Silverman, Ofri Mosenzon, et al.
Circulation (2019) Vol. 139, Iss. 22, pp. 2528-2536
Open Access | Times Cited: 507
Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update
Shannon M. Dunlay, Michael M. Givertz, David Aguilar, et al.
Circulation (2019) Vol. 140, Iss. 7
Open Access | Times Cited: 501
Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
Kevin Damman, Joost C. Beusekamp, Eva M. Boorsma, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 4, pp. 713-722
Open Access | Times Cited: 375
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology
Russian Journal of Cardiology (2020) Vol. 25, Iss. 11, pp. 4083-4083
Open Access | Times Cited: 336
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Milton Packer, Stefan D. Anker, Javed Butler, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 326-336
Open Access | Times Cited: 329
Heart failure drug treatment
Patrick Rossignol, Adrian F. Hernandez, Scott D. Solomon, et al.
The Lancet (2019) Vol. 393, Iss. 10175, pp. 1034-1044
Open Access | Times Cited: 297
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
Milton Packer, Javed Butler, Faı̈ez Zannad, et al.
Circulation (2021) Vol. 144, Iss. 16, pp. 1284-1294
Open Access | Times Cited: 290
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Yiwen Li, Yanfei Liu, Shiwei Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 257
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
Milton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1270-1278
Open Access | Times Cited: 252
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 230
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 229
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 10, pp. 1279-1287
Open Access | Times Cited: 225
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Clare Arnott, Qiang Li, Amy Kang, et al.
Journal of the American Heart Association (2020) Vol. 9, Iss. 3
Open Access | Times Cited: 216
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 15, pp. 1845-1855
Open Access | Times Cited: 206
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
Milton Packer
Diabetes Care (2020) Vol. 43, Iss. 3, pp. 508-511
Open Access | Times Cited: 202
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Pantelis Sarafidis, Charles J. Ferro, Enrique Morales, et al.
Nephrology Dialysis Transplantation (2019) Vol. 34, Iss. 2, pp. 208-230
Open Access | Times Cited: 173
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
William T. Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
European Heart Journal (2020) Vol. 42, Iss. 6, pp. 700-710
Closed Access | Times Cited: 169
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Giuseppe Defeudis, Rossella Mazzilli, Marta Tenuta, et al.
Diabetes/Metabolism Research and Reviews (2021) Vol. 38, Iss. 2
Open Access | Times Cited: 163
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, et al.
Circulation (2021) Vol. 143, Iss. 22, pp. 2188-2204
Open Access | Times Cited: 158
Page 1 - Next Page

Scroll to top